Therapeutic area intelligence for IgA Nephropathy with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 2

Companies

Novartis →

Otsuka Pharmaceutical →

Assets

Atrasentan →

Sibeprenlimab →

Recent signals(2)

ClinicalJuly 15, 2026

Otsuka initiates trial for Sibeprenlimab in IgA Nephropathy

Otsuka Pharmaceutical is conducting a trial to evaluate the efficacy and safety of Sibeprenlimab in patients with IgA Nephropathy.

ClinicalJuly 15, 2026

Novartis initiates Phase III trial of Atrasentan in pediatric IgAN patients

Novartis is conducting Phase III trial to evaluate the efficacy and safety of Atrasentan in pediatric patients with primary IgAN.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.